Herpes drug inhibits HIV in patients infected with both virusesSeptember 16, 2008Researchers at the U.S. National Institutes of Health (NIH), McGill University and other institutions have discovered how a simple antiviral drug developed decades ago suppresses HIV in patients who are also infected with herpes. Their study was published in the Sept. 11 issue of the journal Cell Host and Microbe. An NIH research team led by Dr. Leonid Margolis made the initial discovery, while Dr. Matthias Gotte, Associate Professor in Biochemical Virology at McGill's Department of Microbiology and Immunology, along with colleagues at Emory University, helped explain the precise molecular mechanisms. According to Dr. Gotte, HIV/herpes co-infection rates are very high and carry significant health burdens for those patients who are already coping with HIV. "In co-infected individuals, HIV disease progression is enhanced by the presence of herpes," he explained. "Why this is the case is not clear, but there's a lot of evidence for it. Moreover, if you're infected with HIV and herpes, it makes it easier for you to transmit HIV to other people. And if you're infected with herpes alone, it makes it easier for you to acquire HIV." Though it was long-believed that acyclovir was an ineffective drug against HIV, it was often prescribed to co-infected patients in the hope of indirectly treating HIV by reducing the herpes load. Surprisingly, the NIH team discovered that in the presence of herpes virus HHV-6, acyclovir actually attacks HIV directly and is able to suppress its reproduction. Acyclovir is a "prodrug," which is converted into its active form only after it is administered to a patient. The research team demonstrated that the herpes virus contains an enzyme not present in HIV and it is this enzyme that converts acyclovir into a compound capable of attacking in HIV. Acyclovir by itself is simply inactive against HIV and therefore the drug can only work in people infected with both viruses. The researchers are hopeful this discovery may open a new front in the war on HIV, particularly in parts of the developing world where rates of co-infection are extremely high. "No anti-retroviral kills HIV completely," Dr. Gotte said. "We need to administer at least three drugs to hold it in check. This potentially gives us another weapon in the armory, and it's cheap and accessible, which matters a lot in the developing world." McGill University |
|||||||||||||||||||||
| Related Herpes Current Events and Herpes News Articles New culprit for viral infections among elderly -- an overactive immune response Researchers at Yale School of Medicine have found that exaggerated responses of the immune system explain why the elderly succumb to viral infections more readily than younger people. People with less education could be more susceptible to the flu People who did not earn a high school diploma could be more likely to get H1N1 and the vaccine might be less effective in them compared to those who earned a diploma, new research shows. Exposure to several common infections over time may be associated with risk of stroke Cumulative exposure to five common infection-causing pathogens may be associated with an increased risk of stroke, according to a report posted online today that will appear in the January 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals. UI study reveals second pathway to feeling your heartbeat A new study suggests that the inner sense of our cardiovascular state, our "interoceptive awareness" of the heart pounding, relies on two independent pathways, contrary to what had been asserted by prominent researchers. Shingles raises risk of stroke by 30 percent or more in adults Adults with shingles were about 30 percent more likely to have a stroke during a one-year follow-up than adults without shingles, in a study reported in Stroke: Journal of the American Heart Association. Scientists identify genetic cause of previously undefined primary immune deficiency disease Researchers at the National Institutes of Health have identified a genetic mutation that accounts for a perplexing condition found in people with an inherited immunodeficiency. An HIV-blocking gel for women University of Utah scientists developed a new kind of "molecular condom" to protect women from AIDS in Africa and other impoverished areas. Before sex, women would insert a vaginal gel that turns semisolid in the presence of semen, trapping AIDS virus particles in a microscopic mesh so they can't infect vaginal cells. Scientists learn why even treated genital herpes sores boost the risk of HIV infection New research helps explain why infection with herpes simplex virus-2 (HSV-2), which causes genital herpes, increases the risk for HIV infection even after successful treatment heals the genital skin sores and breaks that often result from HSV-2. College students who feel 'invincible' unlikely to accept vaccines, MU researcher finds Vaccines to protect against sexually transmitted diseases, including HIV and herpes, are being developed and may soon be available to college students. UCSF researchers identify new drug target for Kaposi's Sarcoma UCSF researchers have identified a new potential drug target for the herpes virus that causes Kaposi's sarcoma, re-opening the possibility of using the class of drugs called protease inhibitors against the full herpes family of viruses, which for 20 years has been deemed too difficult to attain. More Herpes Current Events and Herpes News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||